4.5 Article

A novel chemical attack on Notch-mediated transcription by targeting the NACK ATPase

期刊

MOLECULAR THERAPY-ONCOLYTICS
卷 28, 期 -, 页码 307-320

出版社

CELL PRESS
DOI: 10.1016/j.omto.2023.02.008

关键词

-

向作者/读者索取更多资源

In this study, the first small-molecule inhibitor of NACK, Z271-0326, was discovered, which directly blocks Notch-mediated transcription and exhibits potent antineoplastic activity in PDX mouse models.
Notch activation complex kinase (NACK) is a component of the Notch transcriptional machinery critical for the Notchmediated tumorigenesis. However, the mechanism through which NACK regulates Notch-mediated transcription is not well understood. Here, we demonstrate that NACK binds and hydrolyzes ATP and that only ATP-bound NACK can bind to the Notch ternary complex (NTC). Considering this, we sought to identify inhibitors of this ATP-dependent function and, using computational pipelines, discovered the first small-molecule inhibitor of NACK, Z271-0326, that directly blocks the activity of Notch-mediated transcription and shows potent antineoplastic activity in PDX mouse models. In conclusion, we have discovered the first inhibitor that holds promise for the efficacious treatment of Notchdriven cancers by blocking the Notch activity downstream of the NTC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Prolyl-isomerase Pin1 controls Notch3 protein expression and regulates T-ALL progression

G. Franciosa, G. Diluvio, F. Del Gaudio, M. V. Giuli, R. Palermo, P. Grazioli, A. F. Campese, C. Talora, D. Bellavia, G. D'Amati, Z. M. Besharat, C. Nicoletti, C. W. Siebel, L. Choy, A. Rustighi, G. Del Sal, I. Screpanti, S. Checquolo

ONCOGENE (2016)

Article Oncology

NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest

Giulia Diluvio, Francesca Del Gaudio, Maria Valeria Giuli, Giulia Franciosa, Eugenia Giuliani, Rocco Palermo, Zein Mersini Besharat, Maria Gemma Pignataro, Alessandra Vacca, Giulia d'Amati, Marella Maroder, Claudio Talora, Carlo Capalbo, Diana Bellavia, Saula Checquolo

ONCOGENESIS (2018)

Article Oncology

Notch3 contributes to T-cell leukemia growth via regulation of the unfolded protein response

Maria Valeria Giuli, Giulia Diluvio, Eugenia Giuliani, Giulia Franciosa, Laura Di Magno, Maria Gemma Pignataro, Luca Tottone, Carmine Nicoletti, Zein Mersini Besharat, Giovanna Peruzzi, Maria Pelullo, Rocco Palermo, Gianluca Canettieri, Claudio Talora, Giulia D'Amati, Diana Bellavia, Isabella Screpanti, Saula Checquolo

ONCOGENESIS (2020)

Article Oncology

Pharmacological Disruption of the Notch1 Transcriptional Complex Inhibits Tumor Growth by Selectively Targeting Cancer Stem Cells

Annamil Alvarez-Trotta, William Guerrant, Luisana Astudillo, Mohini Lahiry, Giulia Diluvio, Elena Shersher, Hugo Kaneku, David J. Robbins, Darren Orton, Anthony J. Capobianco

Summary: NADI-351 is the first specific small-molecule inhibitor that selectively disrupts Notch1 transcriptional complexes, demonstrating robust antitumor activity without inducing intestinal toxicity, providing a potential therapeutic approach for improved cancer treatment.

CANCER RESEARCH (2021)

Article Biochemistry & Molecular Biology

PIM-induced phosphorylation of Notch3 promotes breast cancer tumorigenicity in a CSL-independent fashion

Sebastian K. J. Landor, Niina M. Santio, William B. Eccleshall, Valeriy M. Paramonov, Ellen K. Gagliani, Daniel Hall, Shao-Bo Jin, Kathe M. Dahlstrom, Tiina A. Salminen, Adolfo Rivero-Muller, Urban Lendahl, Rhett A. Kovall, Paivi J. Koskinen, Cecilia Sahlgren

Summary: Research shows that PIM kinases modulate the signaling output of different Notch paralogs through distinct mechanisms, promoting breast cancer tumorigenesis. Despite losing interaction with CSL after phosphorylation, Notch3 still maintains tumorigenic potential under estrogenic conditions.

JOURNAL OF BIOLOGICAL CHEMISTRY (2021)

Article Cell Biology

NACK and INTEGRATOR act coordinately to activate Notch-mediated transcription in tumorigenesis

Elena Shersher, Mohini Lahiry, Annamil Alvarez-Trotta, Giulia Diluvio, David J. Robbins, Ramin Shiekhattar, Anthony J. Capobianco

Summary: This study identifies the INT complex as a novel co-factor in Notch-mediated transcription that together with NACK activates Notch target genes and leads to cancer cell proliferation.

CELL COMMUNICATION AND SIGNALING (2021)

Article Genetics & Heredity

Enhancers with cooperative Notch binding sites are more resistant to regulation by the Hairless co-repressor

Yi Kuang, Anna Pyo, Natanel Eafergan, Brittany Cain, Lisa M. Gutzwiller, Ofri Axelrod, Ellen K. Gagliani, Matthew T. Weirauch, Raphael Kopan, Rhett A. Kovall, David Sprinzak, Brian Gebelein

Summary: Notch signaling controls various developmental processes by regulating gene expression, with its dependent enhancers recruiting different complexes to mediate transcription through monomeric CSL sites and cooperative dimer sites called SPS. The way these enhancers bind different complexes can lead to significant differences in the level of target gene activation.

PLOS GENETICS (2021)

Article Cell Biology

Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia

Laura Barreyro, Avery M. Sampson, Chiharu Ishikawa, Kathleen M. Hueneman, Kwangmin Choi, Mario A. Pujato, Somchai Chutipongtanate, Michael Wyder, Wendy D. Haffey, Eric O'Brien, Mark Wunderlich, Vighnesh Ramesh, Ellen M. Kolb, Cem Meydan, Yaseswini Neelamraju, Lyndsey C. Bolanos, Susanne Christie, Molly A. Smith, Madeline Niederkorn, Tomoya Muto, Santosh Kesari, Francine E. Garrett-Bakelman, Boris Bartholdy, Britta Will, Matthew T. Weirauch, James C. Mulloy, Zartash Gul, Stephen Medlin, Rhett A. Kovall, Ari M. Melnick, John P. Perentesis, Kenneth D. Greis, Elmar Nurmemmedov, William L. Seibel, Daniel T. Starczynowski

Summary: This study found that dysregulation of immune signaling pathways is associated with oncogenic immune signaling states in acute myeloid leukemia (AML) hematopoietic stem and progenitor cells. Inhibition of the ubiquitin-conjugating enzyme UBE2N disrupted oncogenic immune signaling and promoted cell death in AML cells while sparing normal cells. These findings highlight the potential of interfering with UBE2N function as a therapeutic strategy for AML.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Article Genetics & Heredity

A Drosophila Su(H) model of Adams-Oliver Syndrome reveals cofactor titration as a mechanism underlying developmental defects

Ellen K. Gagliani, Lisa M. Gutzwiller, Yi Kuang, Yoshinobu Odaka, Phillipp Hoffmeister, Stefanie Hauff, Aleksandra Turkiewicz, Emily Harding-Theobald, Patrick J. Dolph, Tilman Borggrefe, Franz Oswald, Brian Gebelein, Rhett A. Kovall

Summary: Notch signaling pathway involves RBPJ variants associated with AOS, encoding proteins with compromised DNA binding activity but retained cofactor binding. This mechanism underlies the dysregulation of Notch target genes in AOS phenotypes.

PLOS GENETICS (2022)

暂无数据